The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

| Description                          | Lot #  | Exp Date   | NDC         | UPC         |
|--------------------------------------|--|--|-------------|-------------|
| NP THYROID ORAL<br>TB30MGACEL100@    |  | 31/22; M329D20-3<br>9D20-1 03/31/22  | 42192032901 | 34219232901 |
| NP THYROID ORAL<br>TB90MGACEL100@    | 09/30/21; M331<br>M331J19-2A 08,   | 30/21; M331K19-2<br>LJ19-6A 08/31/21;<br>/31/21; M331J19-11<br>LJ19-10A 08/31/21;<br>30/21   | 42192033101 | 34219233101 |
| NP THYROID ORL<br>TB<br>60MGACEL100@ | 03/31/22; M330<br>M330J19-2A 08,<br>08/31/21; M330<br>M330J19-6A 08,<br>09/30/21; M330 | /30/21; M330D20-1<br>0D20-2 03/31/22;<br>/31/21; M330J19-4A<br>0J19-5A 08/31/21;<br>/31/21; M330K19-1A<br>0K19-9 09/30/21;<br>/31/21; M330J19-7A | 42192033001 | 34219233001 |
| NP THYROID TAB<br>15MG ACE 100@      |  | 31/22; M327D20-3<br>7H19-3A 07/31/21;<br>30/21   | 42192032701 | 34219232701 |
| NP THYROID TB<br>120MGGACEL100@      | 09/30/21; M328<br>M328J19-6A 08,<br>08/31/21; M328<br>M328J19-3A 08,                   | 2/31/21; M328K19-2<br>3J19-7A 08/31/21;<br>/31/21; M328J19-5A<br>3J19-4A 08/31/21;<br>/31/21; M328J19-11<br>3K19-4A 09/30/21;<br>/31/21          | 42192032801 | 34219232801 |

Acella is recalling the above items/lots due to testing that has found these lots to be sub potent; the product contains less than 90% of the labeled amount of Levothyroxine (T4) or Liothyronine (T3). This recall is to the consumer level. Affected product started shipping March 4, 2020.